5Marcucci R,Gori AM,Paniccia R,et al. Residual platelet reac- tivity is associated with clinical a,ad laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy[J]. Atherosclerosis, 2007, 195 ( 1 ): 217- 223.
6Fisher M, Cushman M, Knappertz V, et al. An assessment of the joint association of aspirin and statin use with C-reactive protein eoncentration[J]. American Heart Journal, 2008, 156 (1): 106-111.
7Markuszewski L, Rosiak M, Golanski J, et al. Reduced blood platelet sensitivity to aspirin in coronary artery disease: Are dyslipidaemia and inflammatory states possible factors predis posing to sub-optimal platelet response to aspirin? [J]. Basic Clinical Pharmacology Toxicology, 2006,98 ( 5 ) : 503-509.
8LaPointe MC, Mendez M, Leung A, et al. Inhibition of cycloox- ygenase-2 improves cardiac function after myocardial infarction in the mouse [J]. Am Journal Physiology Heart Circulation Physiology, 2004,286 ( 11 ) : 1416-1424.
9Kimura T,Iwase M, Kondo G, et al. Suppressive effect of se- lective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils[J]. Int Immunopharmacol, 2003, 3 (11 ): 1519- 1528.
10Cucoranu I, Clempus R, Dikalova A, et al. NAD(P) H oxidase4 mediates trans-forming growth factor-β1-induced diSferentia- tion of cardiac fibroblasta into myofibroblasts[J]. Circulation Research, 2005,97 (9) :900-907.
